Biotech | December 14, 2021
Moderna to set up mRNA vaccine manufacturing facility in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The company will manufacture a cancer immunotherapy product from 2022
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The platform’s technology works as a compression algorithm for molecular testing
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Sputnik M is a new member of the Sputnik vaccines family
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Subscribe To Our Newsletter & Stay Updated
